Protagonist Therapeutics, Inc. (PTGX)

Market Cap	2.31B
Revenue (ttm)	434.43M
Net Income (ttm)	275.19M
Shares Out	59.60M
EPS (ttm)	4.23
PE Ratio	9.16
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	583,973
Open	39.60
Previous Close	38.49
Day's Range	38.44 - 39.90
52-Week Range	24.22 - 48.89
Beta	2.21
Analysts	Strong Buy
Price Target	57.13 (+47.43%)
Earnings Date	Feb 21, 2025

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an oral...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: PTGX
• Website: https://www.protagonist-inc.com

Analyst Forecast

According to 8 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price forecast is $57.13, which is an increase of 47.43% from the latest price.

Price Target

$57.13

(47.43% upside)

Analyst Consensus: Strong Buy